Naimushin Ya A, Mazurov A V
Russian Cardiology Research Center, Moscow, Russia.
Platelets. 2004 Nov;15(7):419-25. doi: 10.1080/09537100410001721333.
In this study we investigated mechanisms of platelet interaction with von Willebrand factor (vWF) induced by activating anti-glycoprotein (GP)IIb-IIIa antibody CRC54 directed against LIBS (ligand-induced binding site epitope) in GPIIIa. It was demonstrated that aggregation of washed platelets (measured in Born aggregometer) could be stimulated by CRC54 not only in the presence of fibrinogen but vWF as well. The level of aggregation induced in the presence of saturating concentrations of vWF (approximately 80 microg/ml) was even higher than that in the presence of 1 mg/ml of fibrinogen. Aggregation supported by vWF unlike fibrinogen supported aggregation was almost completely inhibited not only by GPIIb-IIIa antagonists (F(ab')2 fragment of blocking anti-GPIIb-IIIa antibody CRC64 and peptidomimetic aggrastat) but also by anti-GPIb blocking antibody AK2. Aggregation response induced by CRC54 in the presence of vWF was much lower when normal platelets were substituted with GPIb-deficient platelets and this residual aggregation was not affected by anti-GPIb antibody AK2 but still inhibited by anti-GPIIb-IIIa blocking antibody fragment. CRC54-induced aggregation supported by vWF (as well as by fibrinogen) was only partially inhibited by prostaglandin E1, indicating that at least its initiation does not require activation of platelets. CRC54, both in the presence of vWF and fibrinogen, failed to stimulate serotonin secretion at physiological Ca2+ concentration of 1 mM, although substantial release reaction was detected when Ca2+ concentration was decreased to 0.1 mM. CRC54 could also stimulate platelet interaction with immobilized vWF and fibrinogen. However, unlike platelet aggregation in suspension mediated by flow phase vWF, platelet adhesion to adsorbed vWF (in a same way as to fibrinogen) was inhibited only by GPIIb-IIIa but not GPIb antagonists. The data obtained indicated that vWF support platelet aggregation induced by activating anti-GPIIb-IIIa via interaction with two receptors - activated GPIIb-IIIa and GPIb.
在本研究中,我们调查了激活抗糖蛋白(GP)IIb-IIIa抗体CRC54诱导血小板与血管性血友病因子(vWF)相互作用的机制,该抗体针对GPIIIa中的配体诱导结合位点(LIBS)表位。结果表明,洗涤后的血小板聚集(用玻恩血小板聚集仪测量)不仅在纤维蛋白原存在时可被CRC54刺激,在vWF存在时也可被刺激。在vWF饱和浓度(约80μg/ml)存在下诱导的聚集水平甚至高于在1mg/ml纤维蛋白原存在下的聚集水平。与纤维蛋白原支持的聚集不同,vWF支持的聚集不仅几乎完全被GPIIb-IIIa拮抗剂(阻断性抗GPIIb-IIIa抗体CRC64的F(ab')2片段和拟肽类阿加曲班)抑制,也被抗GPIb阻断抗体AK2抑制。当用缺乏GPIb的血小板替代正常血小板时,CRC54在vWF存在下诱导的聚集反应低得多,这种残余聚集不受抗GPIb抗体AK2影响,但仍被抗GPIIb-IIIa阻断抗体片段抑制。vWF支持的CRC54诱导的聚集(以及纤维蛋白原支持的聚集)仅被前列腺素E1部分抑制,这表明至少其起始不需要血小板激活。在生理Ca2+浓度1mM时,CRC54在vWF和纤维蛋白原存在下均未能刺激5-羟色胺分泌,尽管当Ca2+浓度降至0.1mM时检测到大量释放反应。CRC54还可刺激血小板与固定化的vWF和纤维蛋白原相互作用。然而,与流动相vWF介导的悬浮血小板聚不同,血小板对吸附的vWF的黏附(与对纤维蛋白原的黏附方式相同)仅被GPIIb-IIIa拮抗剂抑制,而不被GPIb拮抗剂抑制。获得的数据表明,vWF通过与两种受体——活化的GPIIb-IIIa和GPIb相互作用,支持激活抗GPIIb-IIIa诱导的血小板聚集。